Royalty Pharma company profile

RPRX · NASDAQ · USD

Compare Royalty Pharma
$68.68Change from previous close: +0.23%Absolute change: +$0.16

Close · November 17, 2026

Company profile

Royalty Pharma has 100 employees and is headquartered in New York, United States.

Royalty Pharma plc is known by its royalty portfolio on medicines, which covers about 35 marketed therapies and around 20 development-stage product candidates. The company buys biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, with a portfolio spanning rare disease, oncology, neuroscience, infectious disease, hematology and diabetes. It also has a research and development funding collaboration to advance JNJ-4804, an investigational medicine for autoimmune diseases.

In the fiscal year ended December 2025, the company reported revenue of $2.4 billion, up 5.1% from the previous year, and net income of $770.9 million. Royalty Pharma was founded in 1996 and is headquartered in New York, New York, and it employs 100 people.

Company facts

Industry
Biotechnology
Headquarters
110 East 59th Street, 10022, New York
Employees
100
Chief executive
Pablo Legorreta
Founded
1996
Fiscal year
January - December
Listing
RPRX · NASDAQ
Currency
USD
ISIN
GB00BMVP7Y09

Royalty Pharma and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Royalty PharmaRPRXUnited States$39.4B10064.4%45.4
Revolution MedicinesRVMDUnited States$37.27B883-853.0%—
BeOne MedicinesONCUnited States$46.98B12,00017.8%52.7
Roivant SciencesROIVUnited States$28.64B721-3,226.3%—
InsmedINSMUnited States$26.96B1,664-41.7%—
argenxARGXUnited States$59.8B1,86331.9%32.9

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Royalty Pharma with its competitors